Prothena (NASDAQ:PRTA – Get Free Report) will post its quarterly earnings results after the market closes on Thursday, August 8th. Analysts expect Prothena to post earnings of ($1.01) per share for the quarter.
Prothena (NASDAQ:PRTA – Get Free Report) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.13). The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $3.75 million. Prothena had a negative return on equity of 30.48% and a negative net margin of 193.17%. During the same quarter in the previous year, the company posted ($0.89) earnings per share. On average, analysts expect Prothena to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Prothena Stock Up 4.1 %
PRTA stock traded up $0.81 during trading on Tuesday, hitting $20.59. The company had a trading volume of 137,471 shares, compared to its average volume of 639,781. The firm has a 50-day moving average price of $21.60 and a 200-day moving average price of $24.05. Prothena has a 12 month low of $18.69 and a 12 month high of $63.64. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -6.09 and a beta of 0.21.
Wall Street Analysts Forecast Growth
View Our Latest Report on Prothena
Prothena Company Profile
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Featured Articles
- Five stocks we like better than Prothena
- Pros And Cons Of Monthly Dividend Stocks
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- Stock Sentiment Analysis: How it Works
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.